Abbott said that the MONITOR-HF trial has found the company’s CardioMEMS HF System resulted in enhanced quality of life and a 44% reduction in heart failure hospitalisations for indicated heart failure patients.

CardioMEMS is a sensor of the size of a paperclip which can remotely flag early warning signs to a patient’s clinical team of a deteriorating heart failure condition.

As per new data released from the investigator-sponsored European trial, improvement in patient-reported quality-of-life scores was noted as early as three months following use with Abbott’s remote monitoring sensor.

MONITOR-HF is a randomised trial that featured 348 patients who were recruited in 25 centres in the Netherlands, which is one-third of the hospitals in the European country.

The participants had New York Heart Association (NYHA) Class III heart failure with a history of heart failure-related admission or an urgent care visit needing intravenous diuretics within the last year.

They were assigned randomly to be subjected to haemodynamic monitoring using the Abbott CardioMEMS or the standard of care for management of heart failure using guideline-directed medical therapy (GDMT).

Erasmus Medical Center in Rotterdam, Netherlands associate professor and MONITOR-HF trial principal investigator J.J. Brugts said: “The Dutch health care system is known for its structured approach to heart failure management at outpatient clinics with general access to guideline-directed medical therapies.

“This approach raises the bar, making the MONITOR-HF results even more meaningful given that patients who were already receiving a high standard of care reported significant improvements in their quality-of-life while using the CardioMEMS monitoring system.”

Once inserted in the pulmonary artery during a minimally invasive procedure, the CardioMEMS monitors for pressure fluctuations that suggest worsening heart failure. It transmits daily readings wirelessly to a patient’s clinical team, thereby helping in managing the condition from virtually any location.

Abbott heart failure business chief medical officer Philip Adamson said: “Heart Failure is a global health problem with a devastating impact on patient lives and high rate of morbidity and mortality.

“These results demonstrate once again that a proactive, remote-centered approach using pressure monitoring with CardioMEMS leads to better health outcomes and higher patient satisfaction across multiple health indicators than medication alone.”

The CardioMEMS sensor was approved in 2014 by the US Food and Drug Administration (FDA), which was followed by the European Conformity (CE) mark about two years later.

Recently, Abbott secured FDA approval for its Assert-IQ insertable cardiac monitor for the assessment and long-term monitoring of irregular heartbeats.